COMPANY OVERVIEW

enGene Inc. is a privately-held biotechnology company with a vision to transform medicine by administering gene therapy as an oral drug, allowing repeat dosing as required to achieve long-term therapeutic benefit.

---

LOCATION

Montreal, Quebec, Canada

---

THERAPEUTIC AREAS

Gastrointestinal Disease

Inflammatory Disease

Oncology

---

WEBSITE

https://www.engeneinc.com

---

CAREER WEBSITE

https://www.engeneinc.com/#Careers

---

SOCIAL MEDIA

---

INVESTORS

---

---

PRESS RELEASES

Sep 7, 2023

enGene Appoints Richard Bryce, MBChB, MRCGP, MFPM, as Chief Medical Officer

Feb 14, 2023

enGene announces poster presentation containing interim Phase 1 clinical trial data at the 2023 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium

Feb 2, 2023

enGene Appoints Alex Nichols, PhD as President and Chief Operating Officer

Mar 17, 2022

enGene Appoints James C. Sullivan, PhD as Chief Scientific Officer

Feb 8, 2022

enGene Announces Positive Preliminary Phase 1/2 Data with EG-70 in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

For More Press Releases

---